FDA Expands Endometrial Cancer Indication for Jemperli With Chemotherapy

The FDA has approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer. Dostarlimab-gxly previously was approved with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent endometrial cancer that is mismatch repair–deficient (dMMR) or microsatellite instability-high (MSI-H).

Efficacy was evaluated in RUBY